Pharmacovigilance Archives - Well Referenced

Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database

This 2025 study conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) to identify drugs associated with noninfectious myocarditis. Analyzing data from 2004 to 2024, the researchers found 10,763 reports of noninfectious myocarditis. The top five drugs with the highest reporting odds ratios (RORs) were phendimetrazine tartrate

June 26, 2025 No Comments

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

This 2022 pharmacovigilance study analyzed FDA Adverse Event Reporting System (FAERS) data to assess the association between GLP-1 receptor agonists (GLP-1 RAs) and acute cholecystitis. The analysis revealed a notable number of reports linking GLP-1 RAs, such as liraglutide and semaglutide, to cases of acute cholecystitis. The proposed mechanism involves

June 26, 2025 No Comments

Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus

This 2009 nested case-control study analyzed data from the UK General Practice Research Database, encompassing 165,958 patients aged ≥30 years with depression but without diabetes at baseline. Over a follow-up period, 2,243 incident diabetes cases and 8,963 matched controls were identified. The study found that recent long-term use (≥24 months)

June 26, 2025 No Comments

The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database

This 2020 pharmacovigilance study analyzed data from the FDA Adverse Event Reporting System (FAERS) to assess cardiovascular safety signals associated with antiobesity medications. The researchers focused on drugs including lorcaserin, phentermine, orlistat, and naltrexone/bupropion. Findings indicated that lorcaserin was associated with reports of valvulopathy and cardiac disorders, while phentermine was

June 26, 2025 No Comments

Tag: Pharmacovigilance

Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus

The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database